Source-grounded facts extracted from MIMEDX GROUP, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
MIMEDX GROUP, INC.: Increased the number of boards of directors of public companies that the Company's chief executive officer may sit on to three (effective 2026-06-10).
“On June 10, 2026, the Board of Directors of MiMedx Group, Inc. (the “ Company ”) approved an amendment to the Company’s Amended & Restated Bylaws. The amendment increased the number of boards of directors of public companies that the Company’s chief executive officer may sit on to three.”
MIMEDX GROUP, INC. shareholders approved Ratification of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-10 meeting.
“Proposal 3: Ratification of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. For Against Abstain Broker Non-Votes Total Shares Voted 123,687,080 1,640,474 33,411 N/A”
MIMEDX GROUP, INC. shareholders approved Advisory approval of executive compensation at the 2026-06-10 meeting.
“Proposal 2: Advisory approval of executive compensation. For Against Abstain Broker Non-Votes Total Shares Voted 95,158,451 4,369,645 2,223,856 23,609,013”
MIMEDX GROUP, INC. shareholders approved Election of Nine Directors at the 2026-06-10 meeting.
“Proposal 1: Election of Nine Directors. For Against Abstain Broker Non-Votes Joseph H. Capper 99,286,347 2,395,447 70,158 23,609,013 James L. Bierman 96,181,316 5,500,069 70,567 23,609,013 William A. Hawkins, III 98,237,248 3,417,906 96,798 23,609,013 K. Todd Newton 96,493,668 5,219,808 38,476 23,609,013 Tiffany Olson 98,657,185 2,984,080 110,687 23,609,013 Dorothy Puhy 98,645,942 2,993,132 112,878 23,609,013 Martin P. Sutter 97,032,156 4,617,992 101,804 23,609,013”
MIMEDX GROUP, INC. reported first quarter 2026 results: revenue $59 million, net income $11 million. Guidance lowered.
“MIMEDX Announces First Quarter 2026 Operating & Financial Results Reports First Quarter Net Sales of $59 Million Revises 2026 Net Sales and Adjusted EBITDA Expectations”
MIMEDX GROUP, INC. reported first quarter ended March 31, 2024 results: revenue Net Sales of $85 Million, net income GAAP Net Income was $9 Million.
“MIMEDX Announces First Quarter 2024 Operating and Financial Results Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales”
Dorothy E. Puhy was appointed as Director at MIMEDX GROUP, INC..
“On February 29, 2024, the Board of Directors (the “ Board ”) of MiMedx Group, Inc. (the “ Company ”), approved an increase in the size of the Board to eleven members and appointed two new members, Ms. Tiffany P. Olson and Ms. Dorothy E. Puhy, to the Board, effective March 1, 2024.”
Tiffany P. Olson was appointed as Director at MIMEDX GROUP, INC..
“On February 29, 2024, the Board of Directors (the “ Board ”) of MiMedx Group, Inc. (the “ Company ”), approved an increase in the size of the Board to eleven members and appointed two new members, Ms. Tiffany P. Olson and Ms. Dorothy E. Puhy, to the Board, effective March 1, 2024.”
MIMEDX GROUP, INC. reported the fourth quarter and full year ended December 31, 2023 results: revenue Fourth quarter and full year 2023 net sales of $87 million and $321 million, net income GAAP Net Income for the fourth quarter and full year 2023 of $53 million and $58 million, respectively.. Guidance reaffirmed.
“On February 28, 2024, MiMedx Group, Inc. (the “ Company ”), issued a press release (the “ Earnings Press Release ”) announcing its results for the fourth quarter and full year ended December 31, 2023.”
MIMEDX GROUP, INC. incurred term loan of $20.0 million senior secured term loan facility with Citizens Bank, N.A. at Alternate Base Rate plus an applicable margin ranging from 1.25% and 2.50% or Te maturing January 19, 2029.
“On January 19, 2024, the Company borrowed $30.0 million under the Revolving Credit Facility and $20.0 million under the Term Loan Facility.”
MIMEDX GROUP, INC. incurred revolving credit of $75.0 million senior secured revolving credit facility with Citizens Bank, N.A. at Alternate Base Rate plus an applicable margin ranging from 1.25% and 2.50% or Te maturing January 19, 2029.
“a customary security agreement. The Credit Agreement provides for senior secured credit facilities in an aggregate principal amount of up to $95.0 million consisting of: (i) a $75.0 million senior secured revolving credit facility (the “Revolving Credit Facility”) with a $10.0 million letter of credit sublimit and a $10.0 million swingline loan sublimit, and (ii) a”
MIMEDX GROUP, INC. terminated Hayfin Credit Agreement with Hayfin Services LLP, as administrative and collateral agent, and the lenders party thereto (effective 2024-01-19).
“The Hayfin Credit Agreement was simultaneously terminated and the guarantees and liens related thereto were released upon the repayment in full of all of the outstanding obligations under the Hayfin Credit Agreement.”
MIMEDX GROUP, INC. entered into Credit Agreement with Citizens Bank, N.A., as administrative agent, and the lenders party thereto valued at aggregate principal amount of up to $95.0 million (effective 2024-01-19).
“On January 19, 2024, MiMedx Group, Inc. (the “Company”) entered into a Credit Agreement (the “Credit Agreement”) with the lenders party thereto (the “Lenders”) and Citizens Bank, N.A., as administrative agent (the “Agent”).”
MIMEDX GROUP, INC. reported the third quarter ended September 30, 2023 results: revenue $81.7 million, net income $8.5 million. Guidance raised.
“operating and financial results for the third quarter 2023, which ended September 30, 2023. Recent Operating and Financial Highlights: • Third quarter 2023 net sales of $81.7 million, an increase of 20.7% over third quarter 2022. • GAAP net income of $8.5 million for third quarter 2023. • Adjusted EBITDA 1 of $17.6 million for third quarter 2023, representing”
William Phelan retired as Chief Accounting Officer at MIMEDX GROUP, INC..
“As a result of this shared decision, Mr. Phelan decided to retire, also effective September 1, 2023.”
Doug Rice changed role as Chief Financial Officer and Chief Accounting Officer at MIMEDX GROUP, INC..
“After discussions with MiMedx Group, Inc. (the “Company”), including Doug Rice, the Company’s recently appointed Chief Financial Officer, William Phelan, who had previously been serving as Chief Accounting Officer, and the Company agreed that it was in the Company’s best interests to combine the roles of Chief Financial Officer and Chief Accounting Officer into a single position, which Mr. Rice assumed, effective on September 1, 2023.”
MIMEDX GROUP, INC. reported second quarter ended June 30, 2023 results: revenue $81.3 million, net income $1.2 million. Guidance raised.
“report on Form 8-K. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 MIMEDX Announces Second Quarter 2023 Operating and Financial Results Records Second Quarter Net Sales of $81.3 Million; an Increase of 21.5% Over the Prior Year Period Increases Full-Year 2023 Guidance for Net Sales Growth Welcomes Highly Successful MedTech Executive as Chief Financial Officer”
Peter Carlson resigned as Chief Financial Officer at MIMEDX GROUP, INC..
“Peter Carlson submitted his resignation as Chief Financial Officer of the Company.”
Doug Rice was appointed as Chief Financial Officer at MIMEDX GROUP, INC..
“Doug Rice has been appointed to serve as Chief Financial Officer of the Company, effective on July 5, 2023.”
Dr. Robert Stein departed as President of Regenerative Medicine business unit at MIMEDX GROUP, INC..
“Dr. Robert Stein’s position as President of the Company’s Regenerative Medicine business unit was eliminated as part of the realignment, and he will be departing from the Company.”
MIMEDX GROUP, INC.: Increased authorized common stock from 187,500,000 shares to 250,000,000 shares (effective 2023-06-14).
“the Company filed the Articles of Amendment with the Secretary of State of the State of Florida, and the Articles of Amendment became effective on June 14, 2023.”
MIMEDX GROUP, INC. shareholders approved Approval of Articles of Amendment to increase authorized common stock from 187,500,000 to 250,000,000 at the 2023-06-13 meeting.
“(4) approved the Articles of Amendment to increase the number of shares of authorized common stock from 187,500,000 to 250,000,000”
MIMEDX GROUP, INC. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm at the 2023-06-13 meeting.
“(3) ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm”
MIMEDX GROUP, INC. shareholders approved Advisory resolution regarding executive compensation at the 2023-06-13 meeting.
“(2) approved an advisory resolution regarding executive compensation”
MIMEDX GROUP, INC. shareholders approved Election of Directors at the 2023-06-13 meeting.
“the shareholders: (1) re-elected James L. Bierman, Dr. Phyllis L. Gardner, Dr. Michael Giuliani, and Dr. Cato Laurencin”
MIMEDX GROUP, INC. reported first quarter 2023 results: revenue $71.7 million, net income net loss of $5.0 million.
“announced operating and financial results for the first quarter 2023, which ended March 31, 2023, including net sales of $71.7 million, net loss of $5.0 million”
Peter M. Carlson departed as Chief Financial Officer at MIMEDX GROUP, INC..
“On March 23, 2023, MiMedx Group, Inc. (the “Company”), announced that Peter M. Carlson, its Chief Financial Officer, had informed the Company of his decision to leave the Company to pursue other opportunities at an effective date to be mutually agreed upon.”
MIMEDX GROUP, INC. reported Full year ended December 31, 2022 results: revenue Net sales of $267.8 million for full year 2022, net income Net loss of $30.2 million for full year 2022, EPS Net (loss) income per common share - basic and diluted of ($0.33).
“Three Months Ended December 31, Twelve Months Ended December 31, (in thousands) (in thousands) 2022 2021 2022 2021 Net sales $ 74,375 $ 67,409 $ 267,841 $ 258,615 Net (loss) income (415 ) 2,215 (30,197 ) (10,285 ) EBITDA 1 2,043 4,427 (20,929 ) 125 Adjusted EBITDA 1 7,317 3,609 3,914 18,726 Net (loss) income per common share - basic $ (0.02 ) $ 0.01 $ (0.33 ) $ (0.15 )”
MIMEDX GROUP, INC. reported Fourth quarter ended December 31, 2022 results: revenue Net sales of $74.4 million for fourth quarter 2022, net income Net loss of $0.4 million for fourth quarter 2022, EPS Net (loss) income per common share - basic and diluted of ($0.02).
“Three Months Ended December 31, Twelve Months Ended December 31, (in thousands) (in thousands) 2022 2021 2022 2021 Net sales $ 74,375 $ 67,409 $ 267,841 $ 258,615 Net (loss) income (415 ) 2,215 (30,197 ) (10,285 ) EBITDA 1 2,043 4,427 (20,929 ) 125 Adjusted EBITDA 1 7,317 3,609 3,914 18,726 Net (loss) income per common share - basic $ (0.02 ) $ 0.01 $ (0.33 ) $ (0.15 )”
MIMEDX GROUP, INC.: Amended and restated Bylaws to address universal proxy rules, incorporate prior Amendment No. 1, and include technical clarifying changes (effective 2023-02-16).
“On February 16, 2023, the Board of Directors (the “ Board ”) of MiMedx Group, Inc. (the “ Company ”) approved an amendment and restatement of the Company’s amended and restated Bylaws (as amended and restated, the “ Amended and Restated Bylaws ”), which became effective the same day.”
K. Todd Newton departed as Interim Chief Executive Officer at MIMEDX GROUP, INC..
“Also on January 30, 2023, the Company announced that K. Todd Newton will step down and cease to serve as Interim Chief Executive Officer of the Company, also effective on January 27, 2023, but will remain on the Board.”
Joseph H. Capper was appointed as Director at MIMEDX GROUP, INC..
“Mr. Capper will also be appointed to the Board of Directors effective on the commencement of his employment with the Company.”
Joseph H. Capper was appointed as Chief Executive Officer at MIMEDX GROUP, INC..
“On January 30, 2023, MiMedx Group, Inc. (the “Company”) announced that the Board of Directors of the Company (the “Board”) has appointed Joseph H. Capper to serve as Chief Executive Officer of the Company, effective on January 27, 2023.”
MIMEDX GROUP, INC. updated its fourth quarter of 2022 and full year 2022 guidance (reaffirmed).
“reaffirming its fourth quarter of 2022 and full year 2022 net sales expectations.”
Ricci S. Whitlow was appointed as Executive Vice President and Chief Operating Officer at MIMEDX GROUP, INC..
“On January 3, 2023, MiMedx Group, Inc. (the “Company”) appointed Ricci S. Whitlow as its Executive Vice President and Chief Operating Officer, and issued a press release in connection therewith, which is included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein.”
Dr. Rohit Kashyap resigned as President, Wound Care and Surgical at MIMEDX GROUP, INC..
“On December 13, 2022, Dr. Rohit Kashyap, President, Wound Care and Surgical, of MiMedx Group, Inc. (the “Company”) tendered a letter indicating that he is resigning from his position at the Company effective January 3, 2023.”
MIMEDX GROUP, INC. entered into Platform Intellectual Property License with Global Health Solutions, Inc. (d.b.a. Turn Therapeutics) valued at Upfront cash payment of $1 million; future payments up to $9.55 million contingent upon FDA 510(k) c (effective 2022-12-07).
“On December 7, 2022, MiMedx Group, Inc. (“MIMEDX” or the “Company”) entered into a Platform Intellectual Property License (the “License Agreement”) with Global Health Solutions, Inc. (d.b.a. Turn Therapeutics or “Turn”), providing MIMEDX an exclusive, worldwide sublicensable license to use Turn’s proprietary antimicrobial technology platform (PermaFusion®) to develop antimicrobial line extensions and new products.”
MIMEDX GROUP, INC. reported third quarter ended September 30, 2022 results: revenue $67.7 million, net income $8.4 million, EPS $ (0.09 ).
“Key Third Quarter 2022 Financial Metrics • Net sales of $67.7 million for third quarter 2022, compared to $63.1 million for the prior year period. • Net loss of $8.4 million for third quarter 2022, compared to a net loss of $2.3 million for the prior year period. • Adjusted EBITDA 1 loss of $0.7 million for third quarter 2022, compared to a gain of $7.0 million for the prior year period. Three Months Ended September 30, Nine Months Ended September 30, (in thousands) (in thousands) 2022 2021 2022 2021 Net sales $ 67,689 $ 63,074 $ 193,466 $ 191,206 Net loss (8,426 ) (2,339 ) (29,783 ) (12,500 ) EBITDA 1 (6,097 ) 41 (22,971 ) (4,302 ) Adjusted EBITDA 1 (724 ) 7,022 (3,402 ) 15,117 Net loss per common share - basic $ (0.09 ) $ (0.04 ) $ (0.31 ) $ (0.15 ) Net loss per common share - diluted $ (0.09 ) $ (0.04 ) $ (0.31 ) $ (0.15 )”
Timothy R. Wright departed as Chief Executive Officer at MIMEDX GROUP, INC..
“On September 15, 2022, the Company entered into a Separation Agreement and General Release with Timothy R. Wright, the former Chief Executive Officer of the Company”
K. Todd Newton was appointed as Interim Chief Executive Officer at MIMEDX GROUP, INC..
“On September 14, 2022, MiMedx Group, Inc. (the “Company”) entered into an Interim Executive Employment Agreement (“Employment Agreement”) with K. Todd Newton, which provides for the following compensation in connection with Mr. Newton’s service as Interim Chief Executive Officer”
K. Todd Newton was appointed as Interim Chief Executive Officer at MIMEDX GROUP, INC..
“appointed K. Todd Newton, a current director of the Company, as the Company’s interim Chief Executive Officer to replace Timothy R. Wright effective immediately.”
Timothy R. Wright was terminated as Chief Executive Officer at MIMEDX GROUP, INC..
“Mr. Wright also ceased to be a member of the board of directors effective upon the termination of his employment as Chief Executive Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.